Wells Fargo upgrades Zimmer Biomet to Overweight
Bullish on the upgrade and target gap, with moderate confidence given this is a single analyst view.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Bullish on the upgrade and target gap, with moderate confidence given this is a single analyst view.
What happened, with direct paths to the underlying reporting
Wells Fargo upgraded ZBH to Overweight and set a $123 target versus the posted price of $101.41, indicating a positive change in analyst stance.
Target: $123
Posted price: $101.41
Analyst firm: Wells Fargo
Analyst: Larry Biegelsen
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.